Experimental cocktail takes on toughest pancreatic cancer

NCT ID NCT07348107

Not yet recruiting Disease control Sponsor: Daniel Breadner Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether adding ATRA, SDK002, and an immunotherapy drug to standard chemotherapy is safe for people with advanced pancreatic cancer that cannot be removed by surgery. Ten participants will receive all five drugs together. The study will also track how long they live without the cancer growing. Because it is a phase 1 trial, safety is the main focus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATRA (all-trans retinoic acid), SDK002 (arsenic trioxide), gemcitabine, nab-paclitaxel, and tislelizumab
What this could lead to: If this combination proves safe, it could point toward a new treatment option for advanced pancreatic cancer that may help patients live longer.
What could go wrong: This is a very early phase 1 study with only 10 people, so the main goal is safety, not effectiveness. The combination may cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Verspeeten Family Cancer Centre

London, Ontario, N6A 5W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.